Compare RR & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RR | DRUG |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Pharmaceuticals and Biotechnology |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 614.9M | 707.1M |
| IPO Year | 2023 | 2020 |
| Metric | RR | DRUG |
|---|---|---|
| Price | $2.30 | $61.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $4.00 | ★ $129.25 |
| AVG Volume (30 Days) | ★ 12.7M | 421.2K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,045,000.00 | N/A |
| Revenue This Year | $75.68 | N/A |
| Revenue Next Year | $78.28 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.99 | N/A |
| 52 Week Low | $1.73 | $23.18 |
| 52 Week High | $7.43 | $123.75 |
| Indicator | RR | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 42.67 | 28.08 |
| Support Level | $1.85 | $49.47 |
| Resistance Level | $2.93 | $61.76 |
| Average True Range (ATR) | 0.25 | 5.26 |
| MACD | -0.09 | -1.94 |
| Stochastic Oscillator | 16.67 | 5.40 |
Richtech Robotics Inc is a robotics and artificial intelligence (AI) technology company focused on developing embodied AI systems that aims to improve the efficiency and productivity of businesses. The company trains proprietary artificial intelligence models on in-house data to operate robotic systems in the real world. It designs, engineers, manufactures, and deploys next generation embodied AI systems to serve a wide range of industries, including food service, retail, industrial manufacturing, automotive, healthcare, and hospitality. The company's offerings include Commercial Robotic Products, Industrial Robotic Products and Data Services. The company generated the majority of its revenue through product revenue (i.e. outright hardware sales).
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.